Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg (R)) with or without hematopoietic stem cell transplantation.
Publication
, Conference
Erba, HP; Stadtmauer, EA; Larson, RA; Sievers, EL; Esrey, EH; Lowenberg, B; Sherman, ML; Herbertson, RK; Appelbaum, FR
Published in: BLOOD
November 16, 2003
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2003
Volume
102
Issue
11
Start / End Page
871A / 871A
Location
SAN DIEGO, CALIFORNIA
Publisher
AMER SOC HEMATOLOGY
Conference Name
45th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Erba, H. P., Stadtmauer, E. A., Larson, R. A., Sievers, E. L., Esrey, E. H., Lowenberg, B., … Appelbaum, F. R. (2003). Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg (R)) with or without hematopoietic stem cell transplantation. In BLOOD (Vol. 102, pp. 871A-871A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
Erba, H. P., E. A. Stadtmauer, R. A. Larson, E. L. Sievers, E. H. Esrey, B. Lowenberg, M. L. Sherman, R. K. Herbertson, and F. R. Appelbaum. “Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg (R)) with or without hematopoietic stem cell transplantation.” In BLOOD, 102:871A-871A. AMER SOC HEMATOLOGY, 2003.
Erba HP, Stadtmauer EA, Larson RA, Sievers EL, Esrey EH, Lowenberg B, et al. Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg (R)) with or without hematopoietic stem cell transplantation. In: BLOOD. AMER SOC HEMATOLOGY; 2003. p. 871A-871A.
Erba, H. P., et al. “Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg (R)) with or without hematopoietic stem cell transplantation.” BLOOD, vol. 102, no. 11, AMER SOC HEMATOLOGY, 2003, pp. 871A-871A.
Erba HP, Stadtmauer EA, Larson RA, Sievers EL, Esrey EH, Lowenberg B, Sherman ML, Herbertson RK, Appelbaum FR. Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg (R)) with or without hematopoietic stem cell transplantation. BLOOD. AMER SOC HEMATOLOGY; 2003. p. 871A-871A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2003
Volume
102
Issue
11
Start / End Page
871A / 871A
Location
SAN DIEGO, CALIFORNIA
Publisher
AMER SOC HEMATOLOGY
Conference Name
45th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology